Brookline downgraded Oncternal Therapeutics to Hold from Buy citing the company’s termination of clinical studies.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ONCT:
- Oncternal Therapeutics trading resumes
- Oncternal Therapeutics Announces Termination of its Clinical Studies and Exploration of Strategic Alternatives
- Oncternal terminates ONCT-534, ONCT-808 studies, explores strategic alternatives
- Oncternal Therapeutics trading halted, news pending
- Oncternal Therapeutics price target lowered to $18 from $19 at H.C. Wainwright